News

Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer’s disease

Zurich, Switzerland - 31.01.2024 Neurimmune aims to develop aducanumab-based therapeutics that can be subcutaneously administered Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid. Aducanumab was granted FDA accelerated approval for the treatment of Alzheimer’s disease. Neurimmune licensed its antibody aducanumab for...

read more

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

Schlieren (Zurich), Switzerland, January 31, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced clearance of a 510(k) submission from the U.S. Food and Drug Administration (FDA) related to its MagnetOs™ Granules. The Company also announced clearance to market in New Zealand...

read more

LUCULLUS® RELEASE NOTES VERSION 24.1.0

Securecell AG has released a new version of Lucullus®. The latest update follows version 23.0.0 and is named version 24.1.0 based on the new version naming convention. With version 24.1.0, many new features were implemented, and a long list of bugs was resolved. The most important changes are: After a thorough...

read more

Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts

ZURICH, Switzerland and NEWTON, Massachusetts, January 23, 2024 (GlobeNewswire). Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the operational readiness of its new proteomics facility in Massachusetts. This US expansion facilitates access to select proteomics contract research organization (CRO) services for our US biopharma customers. The Massachusetts...

read more